Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total value of $669,280.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares of the company’s stock, valued at $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Jim Wassil also recently made the following trade(s):

• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total value of $739,920.00.
• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.80, for a total transaction of $854,400.00.

Vaxcyte Trading Up 1.9 %

PCVX stock opened at $84.86 on Friday. The firm has a market cap of $10.58 billion, a PE ratio of -18.45 and a beta of 0.94. The stock has a 50-day moving average price of $93.19 and a 200-day moving average price of $92.84. Vaxcyte, Inc. has a 1-year low of $53.83 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the company earned ($0.91) earnings per share. On average, analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PCVX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Mizuho raised their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average target price of $145.71.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PCVX. Everence Capital Management Inc. acquired a new stake in Vaxcyte in the fourth quarter worth $301,000. Principal Financial Group Inc. boosted its position in shares of Vaxcyte by 186.2% during the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock worth $6,022,000 after purchasing an additional 34,287 shares in the last quarter. Lord Abbett & CO. LLC grew its stake in shares of Vaxcyte by 26.9% in the 3rd quarter. Lord Abbett & CO. LLC now owns 312,425 shares of the company’s stock valued at $35,701,000 after buying an additional 66,183 shares during the period. Franklin Resources Inc. increased its position in Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after buying an additional 324,560 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in Vaxcyte during the 3rd quarter worth approximately $507,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.